Probi has completed the first commercial production batches of a dairy-free Streptococcus salivarius BLIS K12 at its US manufacturing site. The strains will shortly be offered to customers around the world.
The company entered a strategic partnership with Blis Technologies, as part of a long-term strategic collaboration in 2021. As part of this partnership, the companies signed a licensing and distribution agreement. Probi is now manufacturing BLIS strains at its recently upgraded fermentation facility in Redmond, WA and will shortly be offering these strains to Probi's customers around the world. In addition, the two companies are continuing to collaborate on additional research and development.
Streptococcus salivarius BLIS K12 is part of a portfolio of bacterial strains for supporting natural immune defense and preventing infections of the mouth and throat. The BLIS strains also contribute to a healthy set of teeth and gums. The strains have previously been sold in New Zealand, Australia and Asia, as well as in Europe and in North America.
